Patents by Inventor Philippe Pouletty
Philippe Pouletty has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12257040Abstract: The invention is directed to a method of determining properties in a vessel or the heart (V) of a patient. It comprises the steps of placing an element in a vessel or the heart(V) and determining a propulsion force (2) acting on the element. Furthermore, at least one of acceleration (3) and velocity (4) of the element is determined. At least one property of a neighbouring medium of the element is determined based on the propulsion force and at least one of acceleration (3) and velocity (4) of the element.Type: GrantFiled: August 21, 2020Date of Patent: March 25, 2025Assignee: ARTEDRONEInventors: Philippe Pouletty, Maëlle Bruneau
-
Patent number: 11992499Abstract: A compound of Formula (I): or anyone of its metabolites or a pharmaceutically acceptable salt thereof, for use for treating and/or preventing an inflammatory disease, disorder or condition, wherein each R is independently hydrogen, halogen, —CN, hydroxyl, (C1-C3)fluoroalkyl, (C1-C3)fluoroalkoxy, (C3-C6)cycloalkyl, —NO2, —NR1R2, (C1-C4)alkoxy, phenoxy, —NR1—SO2—NR1R2, —NR1—SO2—R1, —NR1—C(?O)—R1, —NR1—C(?O)—NR1R2, —SO2—NR1R2, —SO3H, —O—SO2—OR3, —O—P(?O)—(OR3)(OR4), —O—CH2—COOR3, (C1-C3)alkyl; each R? is independently hydrogen, (C1-C3)alkyl, hydroxyl, halogen, —NO2, —NR1R2, morpholinyl, morpholino, N-methylpiperazinyl, (C1-C3)fluoroalkyl, (C1-C4)alkoxy, —O—P(?O)—(OR3)(OR4), —CN, a —NH—SO2—N(CH3)2 group, or other groups and further relates to A compound of formula (IV): or a pharmaceutically acceptable salt thereof, for use for treating and/or preventing an inflammatory disease, disorder or condition, wherein V, Z, R, R?, n, and n? are as described above.Type: GrantFiled: December 19, 2019Date of Patent: May 28, 2024Assignees: ABIVAX, INSTITUT CURIE, UNIVERSITE DE MONTIPELLIER, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Philippe Pouletty, Hartmut Ehrlich, Didier Scherrer, Jamal Tazi
-
Patent number: 11911476Abstract: The present invention relates to process for preparing a drug delivery composition comprising the steps of a) preparing a masterbatch comprising a drug and a first polymer by (i) extruding the first polymer, wherein said first polymer has a melting temperature below 140° C.; and (ii) introducing the drug during extrusion of the first polymer, with a drug content between 0.1% and 90%, based on the total weight of the masterbatch; and b) introducing the masterbatch in a polymer-based matrix during production of the drug delivery composition, wherein step a) is performed at a temperature at which the first polymer is in a partially or totally molten state, and step b) is performed at a temperature at which both the first polymer and at least a polymer of the polymer-based matrix are in a partially or totally molten state.Type: GrantFiled: July 25, 2018Date of Patent: February 27, 2024Assignee: PK MEDInventors: Philippe Pouletty, Frédérique Guillamot
-
Patent number: 11826372Abstract: An antitumor pharmaceutical combination includes (i) a compound ABX196 and (ii) at least one chemotherapeutic agent and/or at least one immunotherapeutic agent, for use in the treatment of cancer.Type: GrantFiled: December 6, 2021Date of Patent: November 28, 2023Assignee: ABIVAXInventors: Sandrine Crabe, Didier Scherrer, Hartmut Ehrlich, Philippe Pouletty
-
Patent number: 11278552Abstract: An antitumor pharmaceutical combination includes (i) a compound ABX196 and (ii) at least one chemotherapeutic agent and/or at least one immunotherapeutic agent, for use in the treatment of cancer.Type: GrantFiled: September 14, 2017Date of Patent: March 22, 2022Assignee: AbivaxInventors: Sandrine Crabe, Didier Scherrer, Hartmut Ehrlich, Philippe Pouletty
-
Patent number: 11266667Abstract: The compound ABX196 and pharmaceutical compositions including ABX196 are used in the treatment of bladder cancer.Type: GrantFiled: September 13, 2018Date of Patent: March 8, 2022Assignee: ABIVAXInventors: Sandrine Crabe, Didier Scherrer, Hartmut Ehrlich, Philippe Pouletty
-
Patent number: 10624876Abstract: The present invention relates to compounds of formula (I) and pharmaceutical compositions comprising such compounds, for use for treating and/or preventing endometriosis.Type: GrantFiled: October 23, 2017Date of Patent: April 21, 2020Assignee: BIOKINESISInventor: Philippe Pouletty
-
Publication number: 20180214605Abstract: According to the invention, said tissue endoprosthesis comprises an expandable support structure or stent held between an inner tissue structure and an outer coating consisting of a hemocompatible soft synthetic material which impregnates said inner structure through the openings in said support structure.Type: ApplicationFiled: March 7, 2016Publication date: August 2, 2018Applicant: CarmatInventors: Antoine Capel, Clément Ducros, Philippe Pouletty, Jean-Claude Cadudal
-
Patent number: 9181564Abstract: The present invention relates to composition and methods of producing bioenergy. More specifically, the invention relates to the use of bacterium of the genus Deinococcus and/or related genera for the modification of biomass or biomass derivatives with a view to producing bioenergy products and metabolites.Type: GrantFiled: November 14, 2008Date of Patent: November 10, 2015Assignees: DEINOVE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE MONTPELLIER 1Inventors: Jean-Paul Leonetti, Ivan Matic, Jacques Biton, Philippe Pouletty
-
Publication number: 20140142691Abstract: The invention concerns a minimally invasive valve repair system (2), in particular a mitral valve repair system (2) or a tricuspid valve repair system. The system comprises a valve component (3), in particular a mitral valve component (3) or a tricuspid valve component, holding or adapted to hold a valve (4), in particular a mitral valve (4) or a tricuspid valve, respectively. The system (2) comprises a linker-component (6) by means of witch the valve component (3) is linked or linkable to an anchor support (5), in particular an in particular an aortic valve or aortic anchor support (5) or a pulmonic valve or pulmonary artery anchor support, respectively.Type: ApplicationFiled: November 19, 2013Publication date: May 22, 2014Applicant: Nakostech SARLInventor: Philippe Pouletty
-
Publication number: 20100022846Abstract: This invention relates to methods for monitoring the anatomy of an individual, which methods comprise the steps of: (i) subjecting a healthy or asymptomatic individual to non-invasive analysis techniques, such as imaging or acoustic techniques, to obtain images or data on determined cells, tissue(s) or organs, at different time points over a period of more than one month, preferably over years; (ii) collecting the images or data in a database; (iii) comparing the images or data to the images or data previously acquired for the same individual, in essentially the same conditions; wherein said comparison of images or data obtained at different time points allows definition of non-pathological baseline anatomy for this individual.Type: ApplicationFiled: November 28, 2006Publication date: January 28, 2010Inventors: Philippe Pouletty, Daniel Cohen
-
Publication number: 20060002891Abstract: Novel conjugates are provided comprising a moiety capable of specifically binding to a target cell joined to a selective moiety for binding to an endogenous effector agent, capable of causing cell inactivation or cytotoxicity. Example of conjugates are a ligand for a surface membrane protein, e.g. IL-2 receptor, joined to an ?-galactosyl epitope, or a polysaccharide A or B antigen. The conjugates may be used to specifically destroy cells associated with a pathogenic condition.Type: ApplicationFiled: September 13, 2005Publication date: January 5, 2006Inventor: Philippe Pouletty
-
New amphetamine derivatives, antibodies against them and pharmaceutical compositions containing them
Publication number: 20030171435Abstract: Hapten-carrier conjugates capable of eliciting anti-hapten antibodies in vivo to amphetamines are disclosed. Methods of preparing the hapten-carrier conjugates and therapeutic compositions are also disclosed. A therapeutic composition containing the hapten-carrier conjugate is useful in the treatment of addiction to amphetamines. Passive immunization using antibodies raised against conjugates of the instant invention also is disclosed. The therapeutic composition is suitable for co-therapy with other conventional drugs for treatment of amphetamine abuse.Type: ApplicationFiled: January 23, 2002Publication date: September 11, 2003Applicant: Drug Abuse Sciences, Inc.Inventors: Philippe Pouletty, Jacques Kusmierek, Frederic Koralewski, Herve Galons, Dominique Blanchard, Caroline Gadjou -
Patent number: 6541004Abstract: The ethyl ester of derivatives of benzoyl ecgonine are provided having a linking group at the para position of the benzoyl group. The derivatives are used to bond to immunogenic polypeptides for production of antisera and monoclonal antibodies. The antisera and antibodies find use in assays, for treatment of cocaine overdose and detoxification.Type: GrantFiled: January 4, 2000Date of Patent: April 1, 2003Assignee: DrugAbuse Sciences, Inc.Inventors: Jean-Michel Scherrmann, Philippe Pouletty, Herve Galons
-
Publication number: 20020102659Abstract: The ethyl ester of derivatives of benzoyl ecgonine are provided having a linking group at the para position of the benzoyl group. The derivatives are used to bond to immunogenic polypeptides for production of antisera and monoclonal antibodies. The antisera and antibodies find use in assays, for treatment of cocaine overdose and detoxification.Type: ApplicationFiled: January 9, 2002Publication date: August 1, 2002Inventors: Jean-Michel Scherrmann, Philippe Pouletty, Herve Galons
-
Publication number: 20020009441Abstract: First and second compounds are provided, where the first compound is administered to a mammalian host into blood for covalent bonding to blood components, where the components have an extended lifetime in the blood stream. The first compound comprises an active functionality and an agent of interest or a first binding entity. A second compound may be subsequently administered to the patient, which comprises a second binding entity, complementary to the first binding entity and an agent of interest. By virtue of binding to long-lived blood components, the half-life of the agent of interest is greatly extended in vivo.Type: ApplicationFiled: August 3, 2001Publication date: January 24, 2002Inventors: Philippe Pouletty, Christine Pouletty
-
Patent number: 6249717Abstract: A liquid medication dispenser apparatus which provides for user-friendly medication measurement and compliance. The apparatus measures and dispenses liquid medication doses and records the time and dose sizes for up to one year. The recorded information can then be downloaded to a personal computer for evaluation of patient compliance. A disposable, motor driven pump is used to provide a very wide range of medication dispensation volumes, while maintaining full accuracy and reducing the risks of patient errors as might occur with a manual dispense system.Type: GrantFiled: June 2, 1997Date of Patent: June 19, 2001Assignee: SangStat Medical CorporationInventors: Laurence R. Nicholson, Cliff Tyner, Debra L. McEnroe, Robert A. Britts, Philippe Pouletty, Ralph Levy
-
Patent number: 6114508Abstract: The ethyl ester of derivatives of benzoyl ecgonine are provided having a linking group at the para position of the benzoyl group. The derivatives are used to bond to immunogenic polypeptides for production of antisera and monoclonal antibodies. The antisera and antibodies find use in assays, for treatment of cocaine overdose and detoxification.Type: GrantFiled: August 25, 1998Date of Patent: September 5, 2000Assignee: DrugAbuse Sciences, Inc.Inventors: Jean-Michel Scherrmann, Philippe Pouletty, Herve Galons
-
Patent number: 6103233Abstract: First and second compounds are provided, where the first compound is administered to a mammalian host into blood for covalent bonding to blood components, where the components have an extended lifetime in the blood stream. The first compound comprises an active functionality and an agent of interest or a first binding entity. A second compound may be subsequently administered to the patient, which comprises a second binding entity, complementary to the first binding entity and an agent of interest. By virtue of binding to long-lived blood components, the half-life of the agent of interest is greatly extended in vivo.Type: GrantFiled: June 7, 1995Date of Patent: August 15, 2000Assignee: Conjuchem, Inc.Inventors: Philippe Pouletty, Christine Pouletty
-
Patent number: 5939273Abstract: Compounds and libraries are labeled with a galactosyl epitope and then screened in accordance with an assay involving cells having a characteristic of interest. Conveniently, the screening may embody target cells, where the compounds are brought in contact with the cells. Each of the compounds carries with it the information of its identity or method of synthesis. After washing away non-specifically bound compounds, blood may be applied to the cells, whereby antibody binding to the galactosyl epitope initiates the complement cascade. Plaques are identified and the compound associated with the plaque identified. The formation of the plaque demonstrates that the compound has specific affinity for the target cell, binding of the compound to the cell does not interfere with binding of the antibody, and that the complex is capable of cytotoxic activity by means of the complement cascade.Type: GrantFiled: October 2, 1997Date of Patent: August 17, 1999Assignee: SangState Medical CorporationInventors: Alexander R. Lussow, Roland Buelow, Philippe Pouletty